Shares of Rapt Therapeutics soared 60% after GSK announced a $2.2 billion acquisition deal. Investors will receive $58.00 per share, a 65% premium. GSK gains global rights to Rapt’s experimental food allergy treatment, ozureprubart. The drug is in phase 2 trials and targets the protein responsible for 94% of severe food allergies.

The acquisition is set to close in the first quarter pending regulatory approval. Over 17 million Americans have food allergies, with 1.3 million facing severe reactions. Consider that Rapt Therapeutics was not included in the Motley Fool Stock Advisor’s list of the top 10 stocks to buy now. The list has historically produced significant returns for investors.

Read more at Yahoo Finance: Why Rapt Therapeutics Stock Soared Today